Pan-cancer analysis reveals the relationship between SLC47A1 immune infiltration and clinical prognosis of human tumors

Abstract

Objective

Objective To analyze the differential expression and prognosis of Solute Carrier Family 47 Member 1 (SLC47A1) in human pan-cancer using bioinformatic methods to explore the prognostic value of SLC47A1 for human pan-cancer and to determine its immune regulatory role.

Methods

The Cancer Genome Atlas (TCGA) pan-cancer database was used to analyze the diagnostic and prognostic value of SLC47A1, as well as its expression patterns. Pearson correlation analysis was used to evaluate the relationship between SLC47A1 and stromal scores, immune scores, tumor mutation burden (TMB), and microsatellite instability (MSI). The correlation between SLC47A1 and specific tumor immune subtypes was analyzed using the Tumor-Immune System Interactions Database (TISIDB). Analysis of differential methylation of SLC47A1 and prognostic analyses were performed using the Disease Meth and TCGA Pan-Cancer databases.

Results

SLC47A1 was abnormally expressed in 17 tumors and shows low expression levels in 11 tumor tissues. Low expression of SLC47A1 was associated with poor prognosis and diagnosis. Moreover, SLC47A1 was also involved in tumor microenvironment regulation. SLC47A1 methylation was disordered in 15 tumors, and disordered methylation was associated with survival.

Conclusion

Overall, these results indicate that SLC47A1 may serve as an important prognostic biomarker and may correlate with tumor immunity in human pan-cancer.